Antibodies against cells of fetal origin
View Patent ↗This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood.
1. A method for producing antibodies specific for fetal CD36+ cells, comprising the steps of:
(a) stimulating CD34+ adult cells isolated from a biological fluid to express CD36;
(b) isolating differentiated adult cells stimulated according to step (a);
(c) stimulating CD34+ fetal cells isolated from fetal tissue to express CD36;
(d) isolating differentiated fetal cells stimulated according to step (c);
(e) isolating total RNA from the adult cells of step (b) and the fetal cells of step (d);
(f) analyzing said isolated total RNA of step (e) to identify genes encoding cellular proteins that are significantly expressed by the isolated fetal cells, but not significantly expressed by the isolated adult cells;
(g) obtaining cellular proteins or peptides thereof that are encoded by the genes identified in step (f); and
(h) preparing antibodies against the cellular proteins or peptides thereof obtained in step (g) using the cellular proteins or peptides thereof as antigens.
2. The method according to claim 1 , wherein the isolated CD34+ cells are incubated in the presence of the cytokines Flt-3 ligand, TPO (thrombopoietin), and SCF (stem cell factor).
3. The method according to claim 1 , wherein the CD34+ cells are stimulated to express CD36 by incubating the cells in the presence of:
(i) EPO (erythropoietin), SCF, Interleukin-3 (IL-3), and Interleukin-6 (IL-6);
(ii) EPO, IGF-1 (Insulin-like growth factor-1), and SCF; or
(iii) EPO, SCF, IL-3, and IGF-1.
4. The method according to claim 3 , wherein the isolated CD34+ cells are incubated in the presence of hematopoietic progenitor growth media (HPGM) supplemented with 2% deionized bovine serum albumin, 150 μg/mL iron saturated human transferrin, 900 μg/mL ferrous sulfate, 90 μg/mL ferric nitrate, 100 μg/mL insulin, 30 μg/mL soybean lecithin, and 7.5 μg/mL cholesterol and 1×10 −6 M hydrocortisone.
5. The method according to claim 1 , wherein said analyzing in step (f) comprises hybridizing cDNA prepared from the isolated total RNA from the adult cells of step (e) to a cDNA microarray and hybridizing cDNA prepared from the isolated total RNA from the fetal cells of step (e) to a cDNA microarray.
6. The method according to claim 1 , wherein the biological fluid is maternal blood.